Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-06-02, Stock:LLY, The news for the past five days is as follows:
2020-05-26: NEWS1: Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model.NEWS2: CanSino Biologics' Covid-19 Vaccine Shows Early Promise.NEWS3: Eli Lilly, Junshi Biosciences To Start Human Testing Of Covid-19 Antibodies By Q2.NEWS4: Lilly, Junshi Biosciences plan to start human trials of COVID-19 antibody in Q2.NEWS5: Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies.NEWS6: Lilly, Junshi Biosciences to start human trials of COVID-19 antibodies.NEWS7: Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction.NEWS8: Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure.NEWS9: Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?.
2020-05-27: NEWS1: Sanofi's Dupixent Gets FDA Approval for Eczema in Children.NEWS2: Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio.NEWS3: Zacks.com featured highlights include: Eli Lilly and Company, Quidel, Everbridge and Sprouts Farmers Market.NEWS4: White House announces plan for Medicare enrollees to get insulin for $35 a month.NEWS5: Eli Lilly's COVID-19 therapy development partner AbCellera raises $105 million.NEWS6: Antibody drug tech firm AbCellera raises $105 million as it works on COVID-19.
2020-05-28: NEWS1: Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease.NEWS2: U.S. FDA approves Eli Lilly's diagnostic agent for Alzheimer's disease.NEWS3: Thursday Morning Market Highlights.NEWS4: 3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020.
2020-05-29: NEWS1: FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid.NEWS2: Lilly Cleared by FDA to Market Alzheimer's Detection Drug.NEWS3: Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN.NEWS4: Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates.NEWS5: Lilly gets FDA approval for Alzheimer's diagnostic agent.NEWS6: Eli Lilly Earns Landmark Approval for Alzheimer's Disease Imaging Agent.
2020-06-01: NEWS1: Why Carnival, Royal Caribbean, and Norwegian Cruise Line Stocks Rose Today.NEWS2: Coronavirus update: NJ eyes next reopen phase; protests, curfews fan fears of COVID spread.NEWS3: Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy'.NEWS4: Coronavirus latest: Monday, June 1.NEWS5: 3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity.NEWS6: A new batch of data for Gilead Sciences’ remdesivir points to efficacy but it’s no ‘silver bullet’.NEWS7: Top Stock Picks for Week of June 1, 2020.NEWS8: Coronavirus update: Global case tally tops 6 million as weekend protests spark concerns they will lead to an increase in infections.NEWS9: Eli Lilly Is Already Testing a COVID-19 Antibody Treatment in Humans.NEWS10: Gilead's stock falls on remdesivir, Eli Lilly begins human study of possible COVID-19 treatment.NEWS11: Dow Jones Erases 150-Point Loss Amid Rising U.S.-China Tensions; Pfizer Dives 8%, But Tesla Surges 6% To Breakout.NEWS12: Gold Little Changed Near $1,750 as U.S. Protests Square off with Reopenings.NEWS13: Eli Lilly Shares Jump After Healthcare Group Doses First Patients in COVID-19 Vaccine Trial.NEWS14: Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer.NEWS15: Cooper Companies (COO) to Post Q2 Earnings: What's in Store?.NEWS16: Eli Lilly’s Taltz Injection Gets FDA Nod For Inflammatory Spine Arthritis Treatment.NEWS17: Eli Lilly Starts Dosing Patients In World’s First Covid-19 Antibody Trial.NEWS18: Eli Lilly starts human study of potential COVID-19 antibody treatment.NEWS19: Eli Lilly starts human study of potential COVID-19 treatment.NEWS20: Lilly initiates Phase 1 clinical trial for a COVID-19 antibody treatment.NEWS21: Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA).NEWS22: Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans.

Answer: Rise